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Total synthesis of the Mycobacterium tuberculosis 
dideoxymycobactin-838 and stereoisomers: Diverse CD1a-
restricted T cells display a common hierarchy of lipopeptide 
recognition  
Janice M. H. Cheng,†[a,c,f] Ligong Liu,†[b,g] Daniel G. Pellicci,[c,f] Scott J. J. Reddiex,[c,f] Rachel N. 
Cotton,[d] Tan-Yun Cheng,[d] David C. Young,[d] Ildiko Van Rhijn,[d,e] D. Branch Moody,[d] Jamie 
Rossjohn,*[f,g,h] David P. Fairlie,*[b,h] Dale I. Godfrey,*[c,g] Spencer J. Williams*[a,g] 
Abstract: Mycobacterium tuberculosis produces 
dideoxymycobactin-838 (DDM-838), a lipopeptide that potently 
activates T cells upon binding to the MHC-like antigen-presenting 
molecule CD1a. M. tuberculosis produces DDM-838 in only trace 
amounts and a previous solid-phase synthesis provided sub-
milligram quantities. We describe a high yielding solution-phase 
synthesis of DDM-838 that features a Mitsunobu substitution that 
avoids yield-limiting epimerization at lysine during esterification, and 
amidation conditions that prevent double-bond isomerization of the 
Z-C20:1 acyl chain, and provides material with equivalent 
antigenicity to natural DDM-838. Isomers of DDM-838 that varied in 
stereochemistry at the central lysine and the C20:1 acyl chain were 
compared for their ability to be recognised by CD1a-restricted T cell 
receptors (TCRs). These TCRs, derived from unrelated human 
donors, exhibited a similar spectrum of reactivity towards the panel 
of DDM-838 isomers, highlighting the exquisite sensitivity of 
lipopeptide-reactive T cells for the natural DDM stereochemistry.  
Introduction 
Humans express four antigen-presenting proteins (CD1a, CD1b, 
CD1c and CD1d) belonging to the CD1 family, which present 
lipid-based molecules to T cells via their T cell receptors 
(TCRs).[1] CD1a differs from the other CD1 molecules based on 
its constitutive, high-density expression on dendritic cells, 
termed Langerhans cells, in the skin and mucosa.[2] Moreover, 
distinct from the other human CD1 molecules, CD1a possesses 
a cytoplasmic tail that lacks lysosomal targeting motifs. Thus, 
CD1a localizes predominantly at the cell surface where it can 
promiscuously capture foreign or exogenous lipids. The only 
extensively-characterized type of foreign lipidic molecule that 
activates CD1a-restricted T cells is a family of lipopeptides 
isolated from Mycobacterium tuberculosis, termed 
dideoxymycobactins (DDMs).[3] 
The initial discovery of the DDMs was achieved through 
bioassay-guided fractionation using a single T cell clone (CD8-2) 
obtained through stimulation and expansion with a 
chloroform/methanol M. tuberculosis extract.[4] A three-
dimensional X-ray structure of CD1a with a silylated, DDM-like 
lipopeptide showed the fatty acyl chain buried in the A' pocket of 
CD1a with the peptide protruding to the surface of CD1a, where 
it presumably contacts the TCR.[5] The recent development of 
CD1a tetramers and dextramers that bind directly to polyclonal T 
cells in the ex vivo setting has allowed the detection and 
isolation of DDM-reactive T cell clones from small cohorts of 
tuberculosis patients.[6] This suggests that CD1a–DDM reactive 
T cells occur in unrelated individuals and that CD1a–DDM 
tetramers may be useful reagents for the ex vivo diagnosis of M. 
tuberculosis infection. Further, the existence of polyclonal T cells 
in small human cohorts raises the possibility that DDMs could be 
used to immunize or stimulate T cell responses in tuberculosis 
patients.[6] However, the key obstacle to these lines of new 
medical technology development is the absence of an abundant 
supply of DDM. 
DDMs are extremely potent, but comprise less than 10 
parts per million of the cell wall mass of M. tuberculosis, a 
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pathogen, whose laboratory cultivation is slow and cumbersome 
because it must be grown in biosafety level 3 conditions. Thus, 
isolation in high yield from natural sources remains impractical.[3] 
The key challenge for chemical synthesis is that naturally 
occurring DDMs possess a complex depsipeptide backbone 
bearing a range of saturated and unsaturated fatty acyl groups 
linked through an amide to the e-amino group of a lysine residue, 
and an unusual a-methylserine-derived angular methyl group. 
The structure of the most reactive compound, DDM-838 (1, 
Figure 1) was proposed through mass spectrometric and NMR 
analysis,[3a] as well as the preparation of a range of possible 
stereoisomers and matching of their spectroscopic data and 
biological activity to the natural product,[3b] and is consistent with 
the stereochemistry of the biosynthetically-related mycobactins, 
iron-chelating hydroxamic acid siderophores. 
 
Figure 1. DDM-838 (1) and three stereoisomers. 
A previous synthetic approach[3b] to DDM-838 used solid-
phase peptide chemistry to provide sufficient material to help 
clarify the structure of the natural product, yet the poor overall 
yield provided only sub-milligram quantities that are insufficient 
for in vivo studies. Prior work demonstrated that the correct 
stereochemistry at positions a and c (Figure 1), and the angular 
methyl group at position a are necessary for activating the DDM-
reactive T cell clone CD8-2, and that natural DDMs lacking the 
unsaturation in the acyl chain are at least 10-fold less potent for 
T cell activation.[3] In the present work we investigate solution-
based peptide-coupling approaches for the preparation of 
milligram quantities of DDM-838. Through careful isolation of by-
products produced in this process, we identify difficulties with the 
establishment of the key ester linkage that occurs with partial 
epimerization at lysine, a problem that may have occurred in the 
previous approach of Young and coworkers (unpublished). This 
and other problems were overcome by the development of a 
new route that creates the challenging ester linkage through a 
Mitsunobu coupling and allows the preparation of milligram 
quantities of DDM-838 (1). Through the isolation of 
stereochemical isomers of DDM-838 (2-4) we have explored 
structure-activity relationships in antigen recognition by the 
prototypical DDM-reactive T cell clone CD8-2, as well as new 
DDM-reactive clones, and demonstrate the importance of 
peptide and lipid stereochemistry for T cell receptor recognition 
and T cell activation. 
Results and Discussion 
Total synthesis of DDM-838 
 
Young and co-workers reported the synthesis of DDM-838 and 
analogues, emphasizing solid-phase approaches.[3b] For 
assembly of DDM-838 itself, a linear depsipeptide bearing the 
fatty acyl chain was assembled on Fmoc-Lys Sasrin resin. 
Following release of the depsipeptide from the resin, the 
terminal lysine was cyclized to form the caprolactam moiety. 
After extensive HPLC purification, this approach yielded only 
trace quantities of DDM-838 (~95 µg or 2% overall yield), which 
we verified independently. As this synthesis was conducted on 
solid phase, it is difficult to identify the yield-limiting steps. In a 
solution-phase approach, used for the synthesis of analogues 
that lacked the distinguishing a-methyl group, an e-amino-
protected deoxymycobactic acid was coupled to deoxycobactin, 
and the depsipeptide was deprotected prior to attaching the fatty 
acyl chain. This resulted in low yields for both attachment of the 
fatty acyl chain and for formation of the ester linkage. Moreover, 
unexpected doubling of signals in NMR spectra of advanced 
intermediates was attributed to the presence of rotational 
isomers, but could alternatively reflect the formation of undefined 
stereoisomers. With the above issues in mind, we initially sought 
to develop a solution-based synthesis of DDM-838 broadly 
inspired by this earlier study,[3b] but with the intention to fully 
characterize all intermediates and identify yield-limiting steps in 
order to identify an improved synthetic approach.  
The required building block fragments deoxymycobactic 
acid 13, deoxycobactin 16, and Z-C20:1 fatty acid 20 were 
prepared by optimization of the previously described literature 
approaches.[3b] Oxazoline acid 11 was prepared from a-methyl-
L-serine 5, by protection as the methyl ester 6, which was 
condensed with 2-benzyloxysalicylic acid 8 using COMU to 
afford amide 9 (Scheme 1a).[7] Cyclization to the oxazoline 10 
proceeded smoothly with XtalFluor-M in CH2Cl2.[8] Saponification 
of the ester of 10 with LiOH afforded the O-benzyl-protected acid 
11, which was coupled with NH2-L-Lys(Boc)OMe using 
EDC.HCl/HOAt/DMAP. Saponification of 12 afforded 
deoxymycobactic acid 13. Next, deoxycobactin 16 was prepared 
by coupling of (R)-3-hydroxybutyric acid 14 and L-α-amino-ε-
caprolactam hydrochloride 15 in the presence of 
EDC.HCl/HOAt/DMAP (Scheme 1b).[3b] Finally, the Z-C20:1 fatty 
acid 20 was synthesized using Ando's reagent,[9] which enables 
a highly Z-selective Horner-Emmons-Wadsworth coupling. 
Treatment of octadecanol 17 with PCC in CH2Cl2 afforded 
stearylaldehyde 18, which condensed with Ando's reagent[9-10] in 
the presence of DBU/NaI to afford a 9:1 Z:E ratio of alkenes 19 
(use of the Still-Gennari reagent provided the alkenes in a 3:1 
Z:E ratio) (Scheme 1c). These isomers could be separated by 
careful chromatography, prior to saponification to afford the acid 
20. 
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Scheme 1. Synthesis of deoxymycobactic acid 13, deoxycobactin 16, and Z-
C20:1 fatty acid 20.  
Coupling of deoxymycobactic acid 13 with deoxycobactin 
16 was explored under a range of esterification conditions using 
assorted peptide coupling reagents. In general, the esterification 
reactions were slow and low yielding, and occurred with varying 
amounts of epimerization at lysine. The best results were 
achieved using DIC/HOAt in the presence of 1.5 eq of DMAP, 
which afforded a 1:1 ratio of S-21/R-21 (Scheme 2). Importantly, 
the O-benzyl protected epimeric intermediates 21 were 
separable by preparative t.l.c., but stereochemical assignment 
was not possible at this stage. Each isomer was individually 
carried through to the lipopeptide by deprotection of benzyl and 
Boc groups (to give S- and R-22), then coupled with the Z-C20:1 
acid 20 using EDC.HCl/HOAt/DMAP in the presence of iPr2NEt. 
Each product was formed as a mixture of E and Z isomers, 
which were separated by flash chromatography to afford four 
pure DDM isomers 1-4, and in some cases small amounts of a 
contaminating trifluoroacetamide. The less polar isomer 21 
afforded material whose spectral data matched the natural 
product DDM-838 (1). At this stage the stereochemistry of the 
central lysine was not known, but established later (vide infra). 
 
 
 
 
 
 
 
 
 
Scheme 2. Preparation of DDM-838 (1) and stereoisomers 2-4. Slow = higher polarity product; fast = lower polarity product. a yield over 3 steps from (S)- or (R)-21. 
b analysis of 1H NMR of crude mixture revealed the formation of 1:2:trifluoroacetamide byproduct at a ratio of 6:3:4, presumably derived from residual 
trifluoroacetate anion carried over from step iii. 
The above work, and an alternative approach utilizing a 
different order of assembly that gave improved yields yet also 
suffered from similar problems (see SI for details), highlighted 
two key problems that likely contributed to the low yield of the 
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prior solid- and solution-based syntheses of DDM-838.[3b] The 
first is the difficulty of effecting the esterification of 3-
hydroxybutyramide, which occurred at best in only moderate 
yield and was complicated by epimerization at the central lysine. 
The difficulty of this coupling likely arises from the sterically-
congested nature of the linkage, between an a-branched acid, 
and a secondary alcohol. The propensity for epimerization at the 
central lysine during esterification of the 3-hydroxybutyramide 
group means that the stereochemistry at this position had not 
been unambiguously secured, although the biosynthetic 
relationship of DDM-838 to the mycobactins allows assumption 
of the L-configuration.[11] The second problem was the 
unexpected isomerization of the unsaturated fatty acyl chain, 
and sometimes contamination with a trifluoroacetamide 
byproduct. 
We initially focussed on solving the problem experienced 
with the unexpected formation of E and Z isomers upon 
acylation of S- and R-22 with Z-C20:1 acid 20, and the formation 
of the trifluoroacetamide by-product. By conversion of the 
trifluoroacetate salt of compound 22 to the free base, prior to 
acylation, we were able to avoid trifluoroacetamide formation. 
Treatment of a pure Z-C20:1-Lys model with iPr2NEt did not 
result in double bond isomerization, suggesting that 
isomerization was occurring to the activated acyl-intermediate. 
Attempts to acylate the model amine (Bz-L-Lys-OMe) using 
DIC/HOAt/DMAP, without iPr2NEt, or with pyridine, still led to 
double bond isomerization, suggesting that base-catalyzed 
isomerization is faster than acylation of lysine. Hocking has 
shown that double bond isomerization of cis-crotonoyl chloride 
during reaction with ammonia does not occur when ammonia is 
passed over the surface of an ethereal solution of the acid 
chloride.[12] Inspired by this precedent, we examined pre-forming 
the activated ester by combining DIC and Z-C20:1 20 in CH2Cl2, 
followed by addition of a CH2Cl2 solution of Bz-L-Lys-OMe, 
which afforded the cis-amide as the sole product.  
To overcome the problem with epimerization at the central 
lysine, a Mitsunobu reaction was explored to form an ester bond 
and interchange the roles of the acid and alcohol to nucleophile 
and electrophile, respectively, thereby potentially alleviating the 
steric demands in forming this linkage. In related work, Miller 
and co-workers applied the Mitsunobu reaction in the synthesis 
of Mycobactins S and S2 through coupling of cobactin and 
mycobactic acid fragments in 49 and 50% yield, respectively.[13] 
In a recent article, Tsakos et al. reviewed a large number of 
challenging esterifications, and suggested that performing 
difficult esterification reactions on smaller fragments can often 
avoid yield-limiting side reactions by reducing the number of 
potentially interfering functional groups.[14]  
Based on these considerations we devised a second linear 
approach to DDM-838. Coupling of (S)-3-hydroxybutyric acid 
((S)-14) (rather than (R)-14) to L-α-amino-ε-caprolactam 15 
using EDC.HCl/HOAt/DMAP and afforded the deoxycobactin 23 
(Scheme 3).[3b] Mitsunobu coupling of 23 with Fmoc-L-Lys(Z)-OH 
in the presence of Ph3P/DIAD afforded the ester 24 with the 
stereochemistry of 3-hydroxybutyrate inverted, and an 
elimination by-product 25 inseparable by flash chromatography. 
While the yield of this reaction was modest, no epimerization at 
lysine was observed. Removal of the Fmoc group with piperidine 
allowed separation of the alkene 25 by chromatography and 
afforded pure amine 26 in 26% yield over two steps. 
Condensation of amine 26 and oxazoline acid 11 afforded the 
depsipeptide 27. Global deprotection of depsipeptide 27 with H2 
over Pd/C gave enantiomerically-pure amine S-22, which was 
isolated as a free base and then coupled with the Z-C20:1 acid 
20, this time using only DIC, and afforded DDM-838 1 as a pure 
Z isomer in 49% yield over two steps. The spectral data were in 
agreement with the natural product. By this approach we 
unambiguously established the stereochemistry of DDM-838 (1) 
as SSRS, as well as the configuration of the three new 
stereoisomers (2–4) (Schemes 2 and SI). 
 
Scheme 3. Mitsunobu route to DDM-838 (1). 
Immunological investigation of CD1a-restricted T cell 
clones 
We explored the ability of our synthetic compounds to 
mediate binding interactions between CD1a and TCRs using a 
series of immunological assays that measure either the 
biological potency of compounds in cellular assays (through the 
expression of activation marker CD69) or the mechanistic basis 
of TCR binding to CD1a-lipopeptide complexes (through 
tetramer staining and flow cytometry). We studied several CD1a-
restricted TCR+ clones including autoreactive clones that 
recognize CD1a alone, and those recognizing CD1a presenting 
foreign DDM and related antigens. Initially, we compared the 
biological activity of synthetic DDM-838 (1) prepared here, with 
natural DDM-838 isolated from M. tuberculosis, and material 
synthesized through the solid phase route of Young and 
coworkers.[3b] Titration of lipids into cultures of the native CD8-2 
T cell clone with all three materials and quantification of IFNg 
release by ELISA provided dose-response curves for the two 
synthetic compounds that were essentially identical (Figure 2). 
The slightly lower potency of natural DDM can be explained by 
the presence of small amounts of naturally occurring variants in 
acyl chain length and saturation, which are known to be less 
potent than DDM-838.[3] This result established the chemical 
identity of the synthetic compounds, and concordant activity with 
natural DDM-838. 
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Figure 2. Synthetic and natural DDM-838 possess equivalent ability to 
activate the native CD8-2 T cell clone. Compound 1 prepared herein (solution 
phase); according to Young and co-workers (solid phase);[3b] and isolated from 
M. tuberculosis H37Ra, were incubated with the human T cell clone CD8-2 
and CD1a-expressing K562 myeloid cells[15] over 24 h and IFNg release 
measured by ELISA. DDM-838 isolated from M. tuberculosis contained 25% of 
the saturated analogue DDM-840,[3a] which is less stimulatory than DDM-838. 
Error bars indicate standard deviation among triplicates. Data representative 
of three independent experiments. Controls at 0 nM DDM-838 are for 
experiments including T cells alone, K562 cells alone, and both cell lines. 
The BK6 clone[16] recognizes cellular CD1a when loaded 
with endogenous lipids and does not require DDM.[17] Jurkat 
cells expressing the BK6 TCR were stained brightly by CD1a 
loaded with endogenous lipids (endo, Figure 3) (these 
endogenous lipids are derived from the mammalian HEK293 
GnT1– cells used for expression of CD1a monomers). By 
contrast, staining of Jurkat.BK6 cells was partially or completely 
inhibited by all four DDM analogs, suggesting that DDM lipids 
were loaded into CD1a and affected the TCR binding site. In 
contrast, Jurkat cells transfected with any of three TCRs derived 
from DDM-reactive T cell clones (CD8-2;[4] and Clone 8 and 
Clone 15, isolated from two different subjects with latent 
tuberculosis infection) stained more brightly with CD1a tetramers 
loaded with synthetic DDM-838, compared to CD1a-endo 
tetramers, indicating that synthetic lipopeptide enhances the 
interaction between CD1a and these TCRs. In comparing the 
heirarchy of CD8-2 staining, CD1a tetramers loaded with 
compound 2 (containing the E-C20:1 acyl lipid) stained less 
intensely than compound 1. Compound 3 (bearing the opposite 
stereochemistry at the central lysine residue compared to DDM-
838), and compound 4 (with unnatural stereochemistry at lysine 
and the acyl lipid) showed minimal, if any staining of the DDM-
838-reactive T cell clones. A negative control cell line expressing 
the MR1-restricted TCR, Jurkat.M33,[18] provided only 
background staining levels with all of the CD1a tetramers, 
indicating that the interactions observed with CD1a-DDM 
tetramers were due to specific TCR interactions. These data 
indicate a role of peptide and stereochemistry in T cell response, 
and the highly similar patterns seen among 3 distinct TCRs 
suggests a conserved mechanism of DDM recognition. 
 
 
Figure 3. Reactivity of CD1a-restricted TCR+ Jurkat cell clones to DDM isomers. (a) Flow cytometry (left) of BK6, CD8-2, Clone-8, Clone-15 and M33 TCR 
expressing cells labeled with CD1a-endo tetramers or CD1a tetramers loaded with DDM-838 (cis-SSRS) 1, DDM trans-SSRS 2, DDM (cis-SRRS) 3 and DDM 
(trans-SRRS) 4, or endogenous lipid antigen (Endo). Numbers in the bottom right corner indicate geometric mean fluorescence intensity (gMFI) of staining with 
CD1a-DDM or CD1a-endo. (b) gMFI of each T cell line against endo and DDM isomers 1-4. Data are representative of three independent experiments. 
To determine if synthetic DDMs could also activate cells, 
we next investigated if compounds 1–4 to could cause TCR-
transduced Jurkat cells to express an activation marker, CD69 
(Figure 4). Titration of the DDM-reactive TCR+ CD8-2 cell line 
with compounds 1-4 resulted in a concentration-dependent 
increase in activation with the same pattern of potency as was 
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observed in tetramer-based binding assays. CD1a-autoreactive 
BK6 cells showed no sign of activation by any of the compounds, 
and even showed a concentration-dependent reduction in 
activation. These data are consistent with lipopeptide loading 
into CD1a but reduced binding of CD1a-lipopeptide to the CD8-2 
TCR for compounds 2-4. Titration of the DDM-reactive TCR+ 
clone 8 and clone 15 cell lines with 1-4 showed limited activation 
(data not shown). 
 
Figure 4. Activation of Jurkat cells expressing BK6 and CD8-2 TCRs by C1R 
cells transduced to express CD1a, measured by expression of the activation 
marker CD69. BK6 and CD8-2 expressing cells were co-cultured overnight 
with CD1a-expressing C1R cells in the presence of DDM isomers 1-4 at 
varying concentrations (0.036, 0.12, 0.36, 1.2, 3.6 nM). For BK6 and CD8-2 
expressing cells with a high TCR to GFP ratio, the level of CD69 expression 
was measured as mean fluorescence intensity (MFI). Data is representative of 
three independent experiments. 
Discussion 
Although CD1a is broadly expressed on human 
Langerhans cells and myeloid dendritic cells, efforts to study 
foreign lipid-reactive CD1a-restricted T cells have been limited 
by the availability of the few known bacterial ligands. Although 
DDM-838 has been bound to CD1a and used in small-scale 
studies of tuberculosis patients,[6] this depsipeptidolipid has only 
been available in trace quantities from either natural sources or 
the reported synthetic route. The present work has investigated 
several synthetic approaches to DDM-838; demonstrated a new 
approach that markedly improves yield; and provides insight into 
a conserved mechanism of DDM-recognition by CD1a-restricted 
T cells. The new method utilizes the Mitsunobu reaction to 
construct the challenging ester linkage and provides access to 
milligram quantities of this important mycobacterial antigen. 
Notably, unlike direct esterification methods that caused 
epimerization at the central lysine, this approach generates the 
ester linkage of the depsipeptide in a substitution reaction 
without epimerization permitting an explicit assignment of the L-
lysine stereochemistry of DDM-838. 
The preparation of three diastereomers 2-4 of DDM-838 1 
permitted investigation of structure-activity relationships for 
recognition by DDM-838 reactive CD1a-restricted TCRs, as well 
as the CD1a-autoreactive BK6 TCR. The BK6 TCR+ cell line is 
brightly stained by CD1a loaded with permissive self lipids,[17] 
but less brightly stained with CD1a tetramers treated with 
compounds 1-4. Structural studies have revealed that the BK6 
TCR binds to the A' roof of CD1a, whereas non-permissive 
ligands such as sphingomyelin and sulfatide protrude from the A' 
cleft and disrupt the BK6 TCR-CD1a contact zone.[17] An X-ray 
structure of a silylated mycobactin analogue revealed the alkyl 
chain inserted deep within the A' pocket of the antigen-binding 
groove, with the peptide folded over in the F' pocket and with 
both the caprolactam and salicyl moieties extending outward to 
the predicted plane of the TCR contact.[5] This binary structure, 
as well as molecular modelling studies of CD1a–DDM-838 
complexes,[3] predict that the peptide moiety might block 
approach of the BK6 TCR to CD1a, based on the known docking 
mode of BK6 with CD1a.[17] This prediction is supported by our 
results, which also provides evidence that all four DDM analogs 
bind to CD1a. Furthermore, Jurkat cells expressing the CD8-2, 
Clone 8 and Clone 15 TCRs fail to bind to CD1a tetramers 
loaded with self lipids that are permissive to CD1a–BK6 TCR 
binding. This suggests an alternative TCR recognition mode 
compared to BK6 in which the peptide moiety likely protrudes 
from the groove to facilitate rather than block TCR binding.  
Conclusions 
Our data reveal a conserved spectrum of T cell recognition 
for the panel of DDM isomers for a set of three unrelated CD1a-
DDM-reactive TCRs. The natural form, DDM-838 1 is the most 
potent, while compound 2, which varies in the lipid 
stereochemistry, maintained significant, albeit reduced, activity 
relative to 1. This result is reminiscent of the effect seen upon 
saturation of the acyl chain of DDM-838 to generate DDM-
840,[3a] demonstrating the importance of the cis-D2-unsaturation 
of DDM-838 for its potent antigenicity. The stereochemistry and 
location of this unsaturation (at C2) is unusual and is generated 
by mycobactin synthase N (MbtN).[19] While the biochemical 
function of the unsaturation is unknown, this work confirms its 
importance for antigen recognition. 
The inversion of stereochemistry at the lysine of the 
depsipeptide backbone compromises the activity of lipopeptide 
and this was reflected in the low reactivity of the DDM-reactive 
TCRs to CD1a-compound 3 tetramers, similar to prior studies of 
DDM-838 varying at either the oxazoline or butyrate moieties 
(positions a and c, Figure 1).[3b] The strong attenuation of TCR 
binding and T cell activation by compound 4, which is both 
epimerized at the central lysine and contains the trans acyl chain, 
reinforces these structure-activity relationships. Collectively, 
these results reveal that the stereochemistry of the depsipeptide 
backbone is important for DDM-recognition by CD1a-restricted 
TCRs, and that variation in stereochemistry or saturation in the 
lipid chain leads to partial attenuation of reactivity. The 
recognition of DDM-838 1 by three distinct T cell clones supports 
the biomedical development of these compounds to target the 
naturally occurring polyclonal T cells present in latent TB 
patients.[6] The ability to synthesize larger quantities of DDM-838 
by the solution-phase scheme described here makes possible 
structural and functional studies of TCR recognition of CD1a–
DDM-838 complexes, as well as in vivo studies that use DDM as 
a vaccine component or recall antigens for immunodiagnosis of 
TB.  
Experimental Section 
Expression and purification of CD1a 
CD1a was expressed by recombinant methods in a mammalian 
expression system by cloning of constructs encoding CD1a and b2-
microglobulin in a pHLsec vector[20] as carboxyterminal fusions with the 
leucine zippers Jun (CD1a) and Fos (b2-microglobulin) and a ‘post-zipper’ 
BirA-His6 tag for CD1a. Fusion proteins were expressed by 
cotransfection of HEK293 GnT1– cells with the plasmids pHLsec-CD1a-
Jun-BirA-His6 and pHLsec-b2m-Fos.[20] Purification of CD1a-b2-
microglobulin heterodimers was achieved by immobilized nickel affinity 
followed by size-exclusion chromatography.  
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Solubilization of DDM isomers 
DDM SSRS Z-C20:1 1, DDM SSRS E-C20:1 2, DDM SRRS Z-C20:1 3 
and DDM SRRS E-C20:1 4 were solubilized in a solution of 0.5% 
tyloxapol (Sigma) in Tris-buffered saline, pH 8.0 at 1 mg/mL. To ensure 
each lipopeptide was completely solubilized, 12 rounds of sonication (1 h, 
water bath temperature 25–45°C), vortex (10 sec) and freezing at –20°C 
(20 mins) were performed until the mixture was a homogenous 
suspension.  
Production of CD1a-restricted Jurkat 76 cell lines 
Parental Jurkat 76 cells lack endogenous TCR α-chains and β-chains,[22] 
and therefore TCR specificity is conferred by the transgene. CD1a-
restricted BK6, CD8-2, Clone 8, Clone 15 and control MR1-restricted 
M33.64[23] Jurkat 76 cells were generated as described[24] using retroviral 
transduction whereby green fluorescent protein and an antibody to CD3ε 
(anti-CD3ε) (UCHT1; BD Biosciences) signified successful transduction. 
These have recently been tested and confirmed to be free of 
Mycoplasma.  
Loading of CD1a, production of CD1a tetramers and staining of 
Jurkat 76 cells with CD1a tetramers 
Soluble mammalian CD1a samples were enzymatically biotinylated with 
BirA biotin ligase as previously described.[21] Biotinylated CD1a was 
loaded overnight with each DDM isomer at a molar ratio of 1:6. CD1a 
tetramers were prepared by mixture of streptavidin-phycoerythrin (BD 
Biosciences) with DDM-loaded biotinylated CD1a at a molar ratio of 1:4. 
CD1a-DDM tetramers (35 µL of stock CD1a-DDM tetramers at 2.5 
µg/mL) were incubated overnight with 3 x 104 CD1a-restricted BK6, CD8-
2, Clone 8, Clone 15 and control MR1-restricted M33.64 Jurkat 76 cells, 
generated as described above. CD1a tetramer–positive cells were 
stained with antibody to CD3ε (anti-CD3ε) (UCHT1; BD Biosciences) and 
were analyzed with an LSR Fortessa (BD Biosciences). Data were 
processed with FlowJo software (TreeStar). 
Assay of activation of the human BK6 and CD8-2 Jurkat 76 cell lines 
CD1a-restricted BK6 and CD8-2 Jurkat 76 cells were generated as 
described above. CD1a-expressing C1R cells were generated as 
previously described.[17] 3.33 ´ 103 CD1a-expressing C1R cells were co-
cultured overnight with 2 ´ 104 Jurkat cells (BK6 or CD8-2) and DDM 
isomers 1-4 at varying concentrations (0.036, 0.12, 0.36, 1.2, 3.6 nM). 
The cells were collected by centrifugation, the supernatant was removed 
and the cells were then stained with anti-CD3ε (BV421, UCHT1, BD 
Biosciences), anti-CD69 (PE, FN50, BD Biosciences), anti-CD19 
(APC/Cy7, SJ25C1, BD Biosciences) and 7-AAD (Sigma Aldrich). 
Activation of CD3+, GFP high (top 50%) BK6 and CD8-2 Jurkat 76 cells 
were assessed by upregulation of CD69. Cells were analyzed with an 
LSR Fortessa (BD Biosciences) and data were processed with FlowJo 
software (TreeStar). 
Activation of human T cell clone CD8-2 by three sources of DDM-
838 (1) 
CD1a-expressing K562 myeloid cells have been described previously 
and are routinely tested by flow cytometry to confirm surface CD1a 
expression.[15] DDM-838 from solid-phase synthesis was provided by Dr 
David Young using the reported method.[3b] Natural DDM was purified 
from M. tuberculosis H37Ra as described previously[3b] and characterized 
by electrospray ionization mass spectrometry to be a mixture of DDM-
838 (75%) and DDM-840 (25%). The concentrations of DDM-838 in 
natural DDM and of solution-phase DDM-838 were determined by UV 
spectroscopy absorbance at 306 nm, normalized to absorbance of 80 µM 
solid-phase DDM-838. 5 ´ 104 CD8-2 T cells were incubated with 2.5 ´ 
104 CD1a-expressing K562 cells and serial dilutions of DDM-838 in 150 
µl T cell media for up to 24 hrs at 37 °C. Secreted IFNg in the undiluted 
cell culture media was quantified by standard sandwich ELISA using 
human IFNg antibody clones 2G2 (Thermo-Fisher), biotin-conjugated 
B133.5 (Thermo-Fisher) and streptavidin-horse radish peroxidase (BD 
Pharmingen). Absorbance was measured at 405 nm using a VersaMax 
plate reader (Molecular Devices) and SoftMaxPro software. IFNg 
concentrations were extrapolated from a standard curve in GraphPad 
Prism 6.  
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